Economic evaluation of encorafenib with cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer in France: a cost-effectiveness analysis using data from the BEACON CRC randomised controlled trial

Jean-Baptiste Trouiller,Marine Sivignon,Andy Buckland,Dan Howard,Emilie Clay,Philippe Laramée,Mondher Toumi,Bérengère Macabeo,David Malka,Andrew Poll,Emmanuelle Samalin

doi:10.1136/bmjopen-2022-063700

Economic evaluation of encorafenib with cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer in France: a cost-effectiveness analysis using data from the BEACON CRC randomised controlled trial

Jean-Baptiste Trouiller, Marine Sivignon + Show 9 more

Open Access

https://doi.org/10.1136/bmjopen-2022-063700

Copy DOI

Journal: BMJ Open	Publication Date: Nov 1, 2022
License type: open-access

Affiliation: Creativ-Ceutical (France), Kentech Instruments (United Kingdom), Aix-Marseille University, Pierre Fabre (France), Institut Gustave Roussy, University of Paris-Saclay, Institut Polytechnique de Paris, Pierre Fabre (United Kingdom), Institute of Cancer Research of Montpellier

#Folinic Acid, Fluorouracil And Irinotecan #Cetuximab In Patients + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

ObjectiveThe BEACON CRC randomised controlled trial (NCT02928224) in BRAF-mutant metastatic colorectal cancer (mCRC) patients showed improved overall survival for the combination treatment of encorafenib (BRAF inhibitor) with cetuximab (EGFR inhibitor)...

Full Text